Core Insights - Health Catalyst has announced a strategic partnership with Microsoft to enhance operational, clinical, and financial performance in healthcare through AI-driven innovation [1][2] - The collaboration leverages Health Catalyst's expertise with Microsoft Azure and Azure AI Foundry to provide advanced AI solutions for healthcare organizations [2][4] - The partnership aims to transform data and analytics into actionable insights, driving sustainable performance improvements for healthcare providers [4][5] Company Overview - Health Catalyst is a leading provider of data and analytics technology and services, serving over 1,000 organizations globally [5] - The company offers a cloud-based technology ecosystem, Health Catalyst Ignite™, and AI-enabled data and analytics solutions to improve clinical, financial, and operational outcomes [5] - Health Catalyst has a proven track record of delivering billions of dollars in measurable results, emphasizing its commitment to data-informed healthcare improvement [5] Product Offerings - Healthcare.AI™ and Health Catalyst Ignite™ are currently available on the Azure Marketplace, with additional solutions to be introduced [3] - These offerings enable healthcare organizations to address challenges in data analytics, cybersecurity, financial, and operational improvements [3] Strategic Goals - The partnership is designed to help healthcare organizations achieve their goals for 2025 and beyond by moving from data analytics to reliable actions and sustained outcomes [4] - The collaboration combines machine intelligence with healthcare expertise to accelerate AI-driven outcomes and optimize decision-making [4]

Core Insights - Health Catalyst, Inc. will release its first quarter 2025 operating results on May 7, 2025, after market close [1] - A conference call will be held at 5:00 pm ET on the same day to review the results [1] Conference Call Details - The conference call can be accessed by dialing 800-343-5172 for U.S. participants or 203-518-9856 for international participants, referencing conference ID "HCATQ125" [2] - A live audio webcast will be available online and a replay will be accessible for approximately 90 days [2] Company Overview - Health Catalyst is a leading provider of data and analytics technology and services aimed at improving healthcare outcomes [3] - The company serves over 1,000 organizations globally, utilizing its cloud-based technology ecosystem, Health Catalyst Ignite™, and AI-enabled solutions [3] - Health Catalyst has a proven track record of delivering billions of dollars in measurable results, focusing on transforming complex healthcare data into actionable insights [3]

Core Insights - Health Catalyst, Inc. has launched Health Catalyst Ignite Spark™, a data and analytics solution specifically designed for community health systems, regional hospitals, and multi-site practices [1][2] - Ignite Spark aims to address the challenges faced by smaller community health systems, including shrinking margins and the need for efficient data management [2][3] - The solution is built to integrate with existing systems, providing enterprise-grade analytics while reducing IT burdens and costs [3][4] Company Overview - Health Catalyst is a leading provider of data and analytics technology and services, serving over 1,000 organizations globally [5] - The company focuses on transforming complex healthcare data into actionable insights, leveraging AI-driven solutions to enhance clinical, financial, and operational outcomes [5][6] - Health Catalyst has a proven track record of delivering billions of dollars in measurable results, emphasizing its commitment to improving healthcare through data-informed strategies [5]

Core Insights - Health Catalyst (NASDAQ: HCAT) is highlighted as a valuable addition to the Bio Boom Portfolio, indicating its potential for growth and investment opportunity [1]. Company Overview - The article emphasizes the author's long-term investment in Health Catalyst, suggesting confidence in the company's future performance [2]. - The author has a background in healthcare investment, focusing on innovative companies that develop breakthrough therapies and pharmaceuticals [1]. Investment Strategy - The investment strategy includes a focus on companies with catalysts for potential acquisitions, which may enhance their market value [1].

Group 1 - The stock of Health Catalyst, Inc. (HCAT) is experiencing significant attention due to high implied volatility in the options market, particularly the Apr 17, 2025 $12.50 Call option [1] - Implied volatility indicates the market's expectation of future price movement, suggesting that investors anticipate a significant change in Health Catalyst's stock price, potentially due to an upcoming event [2] - Health Catalyst currently holds a Zacks Rank 3 (Hold) in the Medical Info Systems industry, which is in the top 17% of the Zacks Industry Rank, with no analysts increasing their estimates for the current quarter and two revising them downwards [3] Group 2 - The recent high implied volatility for Health Catalyst may indicate a trading opportunity, as options traders often seek to sell premium on options with high implied volatility, hoping the stock does not move as much as expected by expiration [4]

SALT LAKE CITY, March 11, 2025 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst,"Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced it has repurchased shares of its common stock ("Common Stock") in an aggregate amount of approximately $5 million.These repurchased shares were acquired between March 3, 2025, and March 10, 2025, as part of Health Catalyst's existing share repurchase program approved by its board of directors on Au ...

Health Catalyst (HCAT) Q4 2024 Earnings Call February 27, 2025 06:40 AM ET Company Participants Jack Knight - VP - Investor RelationsDan Burton - CEODan Lesueur - COOJason Alger - Chief Financial OfficerJared Haase - Equity Research AssociateAnne Samuel - Executive DirectorSameer Patel - VP - Equity ResearchScott Schoenhaus - Managing DirectorGabrielle Ingoglia - Equity Research Associate Conference Call Participants Jessica Tassan - Senior Equity Research AnalystJohn Pinney - AnalystDaniel Grosslight - Sen ...

Financial Data and Key Metrics Changes - Total revenue for full year 2024 was $307 million, representing a 4% year-over-year growth, while adjusted EBITDA was $26 million, reflecting a 137% increase year-over-year [17][56] - For Q4 2024, total revenue was $80 million, a 6% increase year-over-year, and adjusted EBITDA was $8 million, above the midpoint of guidance [56][61] - Technology revenue for full year 2024 was $195 million, with Q4 2024 revenue at $52 million, marking a 10% growth year-over-year for the quarter [17][56] Business Line Data and Key Metrics Changes - Technology segment revenue for full year 2024 grew by 4% year-over-year, while professional services revenue was $112 million, representing a 3% increase year-over-year [56][58] - Adjusted gross margin for the Technology segment in Q4 2024 was 65%, a decrease of approximately 200 basis points year-over-year, primarily due to initial deployment costs [58][59] - Professional services segment adjusted gross margin for Q4 2024 was 13%, an increase of approximately 170 basis points year-over-year [59] Market Data and Key Metrics Changes - Health system operating margins are stabilizing and approaching pre-pandemic levels, which is expected to positively impact client adoption of the company's applications [33] - The company anticipates approximately 40 net new platform client additions in 2025, with an average range of $300,000 to $700,000 ARR plus nonrecurring revenue [35][39] Company Strategy and Development Direction - The company is focusing on profitable growth, with an emphasis on technology revenue, which is expected to grow approximately 13% year-over-year in 2025 [69] - The company plans to exit unprofitable ambulatory operations TEMS pilots by mid-2025 to prioritize profitable growth [37][69] - The modular and flexible Ignite platform is expected to drive cross-selling opportunities and improve client retention [78][121] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the operating environment, noting improvements in health system operating margins and the potential for increased client adoption of applications [33][78] - The company expects to see improvements in bookings metrics compared to 2024, driven by the strengthening end market and continued momentum from Ignite [34][39] - Management anticipates that dollar-based retention rate will be approximately 103% under the updated definition for 2025 [36][88] Other Important Information - The company ended Q4 2024 with $392 million in cash and cash equivalents, compared to $387 million in Q3 2024 [63] - The company has made several leadership updates, including the appointment of Dr. Jill Hoggard Green to the Board of Directors [47][50] Q&A Session Summary Question: What is driving the acceleration in platform bookings in 2025? - Management highlighted improvements in the end market, the modularity and lower price point of Ignite compared to DOS, and the ability to cross-sell to existing app clients as key factors driving the expected increase in platform bookings [76][78] Question: Can you discuss the differences in the new Ignite platform versus DOS regarding annual escalators? - Management noted that Ignite contracts typically have more modest annual escalators in the low to mid-single-digit range, making them easier for clients to digest [82][84] Question: How do you control the pace of migrations to Ignite? - Management is working closely with clients to manage the migration pace responsibly, aiming to complete the majority of migrations by mid-2026 [90][92] Question: What is the visibility into growth in technology revenue after Q1? - Management indicated good visibility into technology revenue growth, estimating approximately 10% year-over-year growth for Q1 2025 [130]

Core Insights - Health Catalyst reported revenue of $79.61 million for the quarter ended December 2024, reflecting a 6% increase year-over-year, but fell short of the Zacks Consensus Estimate of $79.83 million by 0.28% [1] - The company's EPS was $0.04, an increase from $0.02 in the same quarter last year, but significantly below the consensus estimate of $0.11, resulting in an EPS surprise of -63.64% [1] Revenue Breakdown - Professional services revenue was $28.01 million, slightly below the five-analyst average estimate of $29 million, with a year-over-year change of +0.1% [4] - Technology revenue reached $51.60 million, exceeding the five-analyst average estimate of $50.83 million, marking a year-over-year increase of +9.6% [4] Profitability Metrics - Adjusted Gross Profit for Professional Services was reported at $3.78 million, slightly below the average estimate of $3.81 million from five analysts [4] - Adjusted Gross Profit for Technology was $33.35 million, surpassing the average estimate of $32.89 million from five analysts [4] Stock Performance - Over the past month, shares of Health Catalyst have returned -14.7%, compared to a -2.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Viewpoint - Health Catalyst (HCAT) reported quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.11 per share, but showing an improvement from $0.02 per share a year ago [1][2] Financial Performance - The earnings surprise for the quarter was -63.64%, with a previous quarter's earnings of $0.07 per share also missing expectations of $0.10 per share, resulting in a -30% surprise [2] - Health Catalyst's revenues for the quarter ended December 2024 were $79.61 million, slightly missing the Zacks Consensus Estimate by 0.28%, compared to $75.08 million in the same quarter last year [3] - Over the last four quarters, the company has surpassed consensus revenue estimates two times [3] Stock Performance - Health Catalyst shares have declined approximately 30% since the beginning of the year, contrasting with the S&P 500's gain of 1.3% [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [7] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.08 on revenues of $82.64 million, and for the current fiscal year, it is $0.38 on revenues of $338.89 million [8] - The estimate revisions trend for Health Catalyst is mixed, and changes in earnings expectations may occur following the recent earnings report [7] Industry Context - The Medical Info Systems industry, to which Health Catalyst belongs, is currently ranked in the bottom 49% of over 250 Zacks industries, suggesting potential challenges ahead [9] - The performance of Health Catalyst may be influenced by the overall outlook for the industry, as top-ranked industries tend to outperform lower-ranked ones significantly [9]